jvim976-sup-0001-TableS1.docWord document32KTable S1. Allocation of horses to replicate and treatment groups in Part 2. Commencement date is shown for each replicate group.
jvim976-sup-0002-TableS2.docWord document36KTable S2. Sample and diagnostic schedule for Part II horses. All diagnostic procedures were performed on study Day 0, and then repeated weekly for the duration of the study (6 weeks for treatment Groups A and B, 2 weeks for Groups C, D, and E) as indicated below.
jvim976-sup-0003-TableS3.docWord document37KTable S3. Summary of clinical findings for horses in Part II. Individual horses were designated M1–M33 and were randomly assigned to 5 treatment groups: Group A (n = 7, control), Group B (n = 7, meloxicam 0.6 mg/kg PO q24h for 6 weeks), Group C (n = 7, meloxicam 1.8 mg/kg PO q24h for 2 weeks), Group D (n = 7, meloxicam 3.0 mg/kg PO q24h for 2 weeks) and Group E (n = 5, phenylbutazone 4.4 mg/kg PO q12h on first day, 2.2 mg/kg q12h for 4 days, then 2.2 mg/kg q24h for 9 days).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.